FDA adds warning about a rare, sudden vision loss to Ozempic, Wegovy, Zepbound and all other GLP-1 drugs
The risk is small and the FDA has not proven the drugs cause it. Anyone who suddenly loses vision in one eye should call a doctor right away.
The U.S. Food and Drug Administration is requiring the makers of all GLP-1 drugs, including Ozempic, Wegovy, Mounjaro and Zepbound, to add a warning about a rare eye condition that can cause sudden and sometimes permanent vision loss, the agency announced in a Nov. 9 drug safety communication.
GLP-1 drugs copy a natural hormone, glucagon-like peptide-1, that the gut releases after eating. It lowers blood sugar and acts on parts of the brain that control appetite. The drugs are widely used for type 2 diabetes and weight loss, and some are also approved to lower the risk of heart attack and stroke, protect the kidneys, treat sleep apnea or treat a type of fatty liver disease, the FDA says. The warning covers 11 brand-name drugs, including the pills Rybelsus and Foundayo, plus generic exenatide.
What the condition is
The condition is called non-arteritic anterior ischemic optic neuropathy, or NAION. It happens when blood flow drops to the front of the optic nerve, the cable that carries signals from the eye to the brain. Its cause is not fully understood. Risk factors may include smoking, diabetes, high blood pressure, sleep apnea, anemia and kidney disease, the FDA says. Someone who has had it in one eye is more likely to get it in the other.
How big the risk is
The FDA pooled 126 clinical trials with more than 134,000 patients. It found 15 probable cases: 10 among people taking a GLP-1 drug and five among people taking a placebo, a dummy treatment. That works out to 6.4 cases per 100,000 patient-years on the drugs, compared with 3.8 on comparison treatments. A patient-year is one person followed for one year. In adults over 50 in general, the condition strikes about 2.3 to 10.2 people per 100,000 each year.
The evidence is mixed. In an FDA study of insurance records for adults with type 2 diabetes, GLP-1 users had a higher risk than people starting one older class of diabetes pills, DPP-4 inhibitors, but not a statistically clear higher risk than people starting another class, SGLT-2 inhibitors such as Jardiance and Farxiga. Animal studies did not show how the drugs could cause the problem. Because diabetes and other risk factors are common among people who take these drugs, the FDA said a potential increased risk exists but did not say the drugs cause it.
What patients should do
- Watch for sudden, painless vision loss in one eye, often noticed on waking; blurry or missing parts of vision, such as blind spots or tunnel vision; colors that look wrong; or hazy central vision.
- Call a health care provider right away if any of these happen. Doctors are told to send suspected cases to an eye specialist promptly.
- Anyone who has already had NAION should talk with a doctor about whether to keep taking a GLP-1 drug. Do not stop a prescribed drug without talking to a doctor first.
- Side effects can be reported to the FDA’s MedWatch program online or by calling 1-800-332-1088.
Source: FDA Drug Safety Communication on GLP-1 drugs and NAION, Nov. 9, 2026.